PROQUAD 3.99 Log10 PFU / 0.5 ML
VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) : 3.99 Log10 PFU / 0.5 ML RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA27/3 STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MEASLES VIRUS LIVE ATTENUATED (EDMONSTON STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MUMPS VIRUS LIVE ATTENUATED (JERYL LYNN STRAIN) : 4.30 Log10 TCID50 / 0.5 ML · DIN 02399229 · MERCK CANADA INC
Health Canada status: MARKETED
What is PROQUAD?
PROQUAD 3.99 Log10 PFU / 0.5 ML contains VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) : 3.99 Log10 PFU / 0.5 ML RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA27/3 STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MEASLES VIRUS LIVE ATTENUATED (EDMONSTON STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MUMPS VIRUS LIVE ATTENUATED (JERYL LYNN STRAIN) : 4.30 Log10 TCID50 / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02399229, held by MERCK CANADA INC, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 09-May-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROQUAD used for?
ProQuad® (measles, mumps, rubella and varicella virus vaccine live) is a vaccine indicated for the prevention of measles, mumps, rubella, and varicella in children 12 months through 6 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02399229 |
|---|---|
| Brand name | PROQUAD |
| Generic / active ingredient | VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) : 3.99 Log10 PFU / 0.5 ML RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA27/3 STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MEASLES VIRUS LIVE ATTENUATED (EDMONSTON STRAIN) : 3.00 Log10 TCID50 / 0.5 ML MUMPS VIRUS LIVE ATTENUATED (JERYL LYNN STRAIN) : 4.30 Log10 TCID50 / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 3.99 Log10 PFU / 0.5 ML |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | J07BD54 MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-May-2014 |
How is it stored and handled?
null
How is it supplied?
(1) a package of 10 single-dose vials of lyophilized vaccine; and (2) a separate package of 10 vials of diluent.
What can be used instead?
Other Canadian products sharing ATC code J07BD54 MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PRIORIX-TETRA | 1000 CCID50 / 0.5 ML | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02297884 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.